Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
Trial ID or NCT#
NCT00377429
Status
NOT RECRUITING
Purpose
The purpose of this study is to determine whether the investigational drug catumaxomab delivered in the planned treatment schedule is a safe and effective treatment for women with advanced ovarian cancer who experience a complete response to chemotherapy.
Official Title
An Open-Label, Single-Arm, Phase II Safety and Tolerability Study of Catumaxomab (Anti-EpCAM x Anti-CD3) in Women With Advanced Epithelial Ovarian Cancer After a Complete Response to Chemotherapy
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Colleen Fitzsimmons
6507243155
View on ClinicalTrials.gov
